Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Disease
- Therapeutic
- Pharmaceuticals
- Veterinary
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 230817
License Grant
Licensor grants to the Licensor, of England, a world-wide, exclusive license, including the right to sublicense, under the Patents, Technical Information, Trademarks and Tradenames to make, have made, use, offer to sell and sell within the Territory, and to import into any country in the Territory, Products in the Field in accordance with the Agreements.
The parties wish to amend the Pfizer Agreements to adjust minimum royalty payment obligations, on-going royalty rates and other provisions.
License Property
The property as listed in the original agreement is
The Products are any or all compositions containing Compound as a therapeutically active ingredient used or useful in the Field.
The Compound means the chemical compound known as selegiline, having the chemical formula (-)-N-alpha-demethyl-N-2-propynlbenzene-ethanamine and all salts and derivatives thereof.
The trademarks means all of the trademarks relating to the Compound ANIPRYL for use in companion animals and owned by Licensor.
Anipryl (selegiline) is a monoamine oxidase inhibitor (MAOI) that treats Cushings Disease and Canine Cognitive Dysfunction Syndrome (senility).
Field of Use
Per the original agreement, the Field means the animal health field excluding the human health field; the phrase companion animal as used herein refers to dogs, cats, and horses. The compound has use at least for Cognitive Dysfunction Syndrome and Cushings Disease.
IPSCIO Record ID: 211881
License Grant
Licensor grants to the Licensor, of England, a world-wide, exclusive license, including the right to sublicense, under the Patents, Technical Information, Trademarks and Tradenames to make, have made, use, offer to sell and sell within the Territory, and to import into any country in the Territory, Products in the Field in accordance with the Agreements.
License Property
The Products are any or all compositions containing Compound as a therapeutically active ingredient used or useful in the Field.
The Compound means the chemical compound known as selegiline, having the chemical formula (-)-N-alpha-demethyl-N-2-propynlbenzene-ethanamine and all salts and derivatives thereof.
The trademarks means all of the trademarks relating to the Compound ANIPRYL for use in companion animals and owned by Licensor.
Anipryl (selegiline) is a monoamine oxidase inhibitor (MAOI) that treats Cushing's Disease and Canine Cognitive Dysfunction Syndrome (senility).
Field of Use
The Field means the animal health field excluding the human health field; the phrase companion animal as used herein refers to dogs, cats, and horses. The compound has use at least for Cognitive Dysfunction Syndrome and Cushings Disease.
IPSCIO Record ID: 2315
License Grant
The Company purchases its supply of l-deprenyl for the production of Anipryl® under a supply agreement,
Field of Use
Anipryl(R) is effective for the treatment of canine (dog) Cushing's Disease and treatment of canine cognitive dysfunction.
IPSCIO Record ID: 5875
License Grant
Licensor hereby grants to Licensee and its Affiliates of England an exclusive license of the Licensed Assets, including a sublicense under the Co-Development Agreement.
License Property
Licensor has certain rights and entitlements, in its own name, in and to trilostane and methods of using trilostane.
Licensor has entered into a Co-Development Agreement dated July 15, 1998 which granted to Licensor certain rights and entitlements (including the marketing and development rights) in and to the chemical compound known as trilostane, an inhibitor of 3a-hydroxysteroid dehydrogenase, and methods of using trilostane.
The drug is an animal health product, Vetoryl® (trilostane) the treatment of Cushing’s disease in dogs.
Field of Use
Licensed Field shall mean, and is limited to, the practice of the Licensed Patents, Licensed Inventions and Licensed Technical Information, in each case, solely for use in animal health applications.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
